Company intelligence / Profile preview
InventVacc Biologicals
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
Overview
InventVacc’s lead program is a novel Haemophilus influenzae type a (Hia) glycoconjugate vaccine currently in Phase 1 clinical trials to assess safety and immunogenicity in adults. The company has successfully completed toxicology studies and manufacturing lots for the Hia vaccine. Other pipeline programs include meningococcal conjugate vaccines and pentavalent/hexavalent pediatric combination vaccines; these are at various preclinical or early development stages.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineGlycoconjugate vaccinemRNA-based drugs
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on InventVacc Biologicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InventVacc Biologicals.